[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thalidomide-enhances-clinical-efficacy-of-cetuximab-combined-with-standard-chemotherapy-for-left-colorectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thalidomide-enhances-clinical-efficacy-of-cetuximab-combined-with-standard-chemotherapy-for-left-colorectal-cancer":13},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100537555","phase-2-thalidomide-enhances-clinical-efficacy-of-cetuximab-combined-with-standard-chemotherapy-for-left-colorectal-cancer-100537555",false,"NCT06279351","Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer","Inclusion Criteria:\n\n1. Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue\u002Fcytology and genetic testing;\n2. Physical state is good: PS 0-2;\n3. Expected survival of more than 3 months;\n4. Aged 18-75 years old;\n5. Have not received systematic chemotherapy before;\n6. Did not receive cetuximab treatment;\n7. Liver, kidney and bone marrow functions are basically normal;\n8. The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks;\n9. Voluntary participation in the group, good compliance, can cooperate with the experiment observation, and sign the written informed consent.\n\nExclusion Criteria:\n\n1. Patients with severe dysfunction of vital organs (heart, liver, kidney);\n2. Patients with other malignant tumors;\n3. Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test);\n4. In the active phase of acute or chronic infectious diseases;\n5. People with a clear history of drug allergy or allergic constitution;\n6. Patients participating in other clinical trials;\n7. Other conditions in which the patient was considered inappropriate to participate in the study.","ALL","18 Years","75 Years",{"count":19,"type":20},96,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application.\n2. To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies.",[13],"RECRUITING","2025-07-11",{"date":29,"type":30},"2025-07-14","ACTUAL",{"date":32,"type":30},"2024-08-11",{"date":34,"type":20},"2025-12-31",{"name":36,"class":37},"Xinqiao Hospital of Chongqing","OTHER"]